

REVIEW ARTICLE

Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration

Claudia Traidl-Hoffmann^{1,2,3}  | Jamie Afghani¹ | Cezmi A. Akdis^{3,4}  | Mübecel Akdis⁴  |
 Handan Aydin⁵ | Katja Bärenfaller⁴  | Heidrun Behrendt⁶ | Thomas Bieber^{3,7} |
 Paul Bigliardi⁸ | Mei Bigliardi-Qi⁸ | Charlotte Menné Bonefeld⁹  | Stefanie Bösch^{10,11} |
 Marie Charlotte Brüggem^{3,10,11}  | Sebastian Diemert¹² | Hans-Werner Duchna^{3,13} |
 Martina Fähndrich¹⁴ | Danielle Fehr^{3,10,11}  | Marc Fellmann¹⁵ | Remo Frei^{3,16,17} |
 Lena H. Garvey^{18,19}  | Raschid Gharbo²⁰ | Mehmet Gökkaya^{1,2} | Karin Grando^{3,10,11} |
 Carole Guillet^{10,11} | Erman Guler²¹ | Jan Gutermuth²² | Nadine Herrmann²³  |
 Dirk Jan Hijnen²⁴  | Claudia Hülpüsch^{1,2,3} | Alan D. Irvine²⁵  | Erika Jensen-Jarolim^{26,27}  |
 Heidi H. Kong²⁸ | Hillel Koren²⁹ | Claudia C. V. Lang^{3,9,10} | Roger Lauener³⁰ |
 Laura Maintz²³  | Pierre-Yves Mantel³ | Emanuel Maverakis³¹ |
 Matthias Möhrenschrager¹³ | Svenja Müller²³  | Kari Nadeau³²  | Avidan U. Neumann^{1,2} |
 Liam O'Mahony^{33,34}  | Fahafahantsoa Rapelanoro Rabenja³⁵ | Harald Renz³⁶  |
 Claudio Rhyner³ | Ernst Rietschel³ | Johannes Ring³⁷ | Caroline Roduit^{16,30}  |
 Mari Sasaki¹⁶  | Mirjam Schenk^{3,38} | Jens Schröder³⁹ | Dagmar Simon⁴⁰  |
 Hans-Uwe Simon^{41,42} | Milena Sokolowska^{3,4}  | Sonja Ständer⁴³ |
 Martin Steinhoff^{44,45,46,47,48,49,50} | Doris Straub Piccirillo³ | Alain Taïeb⁵¹ |
 Roberto Takaoka⁵² | Martin Tapparo⁵³ | Henrique Teixeira²² | Jacob Pontoppidan Thyssen⁵⁴  |
 Stephan Traidl^{55,56}  | Miriam Uhlmann³ | Willem van de Veen⁴ | Marianne van Hage⁵⁷  |
 Christian Virchow⁵⁸  | Andreas Wollenberg^{59,60,61} | Mitamura Yasutaka⁴  |
 Alexander Zink^{62,63}  | Peter Schmid-Grendelmeier^{3,9,10} 

Abbreviations: AA, alopecia areata; AD, atopic dermatitis; AGS, galactose- α 1,3-galactose (α -Gal) syndrome; AMPs, antimicrobial peptides; AS, ankylosing spondylitis; CGRP, calcitonin gene-related peptide; CIDAMPs, Cationic Intrinsically Disordered Antimicrobial Peptides; CNS, central nervous system; CRSWNP, chronic rhinosinusitis with nasal polyps; EE, eosinophilic esophagitis; ETFAD, European Task Force on Atopic Dermatitis; EH, eczema herpeticum; FLG2, filaggrin-2; GAAD, Global Atlas on Atopic Dermatitis; GAF, the 4th Global Allergy Forum; HBD2, human beta-defensin 2; HRNR, Hornerin; HSV, herpes simplex virus; IEC, International Eczema Council; IL, interleukin; ILC, Innate lymphoid cells; JAKi, janus kinase inhibitors; LCEs, late cornified envelope proteins; MOOCs, Massive Open Online Courses; Nr-SpA, non-radiographic ulcerative colitis; PACAP, pituitary adenylate cyclase-activating polypeptide; PN, prurigo nodularis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, axial spondyloarthritis; TARC, thymus and activation-regulated chemokine; TSLP, thymic stromal lymphopoietin; VT, venous thromboembolism; WHO, World Health Organization.

For affiliations refer to page 2618.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2024 The Author(s). *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Correspondence

Claudia Traidl-Hoffmann, Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Email: claudia.traidl-hoffmann@med.uni-augsburg.de

Abstract

The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.

KEYWORDS

allergy treatment, atopic dermatitis, barrier, environment, hygiene hypothesis

1 | INTRODUCTION

Atopic diseases such as atopic dermatitis (AD), allergic rhinitis, asthma and food allergy are common and debilitating conditions that affect people of all ages. They are considered to represent one of the most prevalent non-communicable disease spectrums worldwide and are frequently under-recognized by primary care professionals.¹⁻³ The resulting inadequate treatment poses unnecessary suffering for patients, especially in lower-income groups who often may not have access to adequate treatments and a worse prognosis due to increased severity and chronicity.⁴ Atopic diseases reduce the patients' quality of life and pose substantial socioeconomic burdens on both society and the individual. AD is one of the most prevalent atopic diseases. The first manifestations of AD usually appear early in life and often precede other allergic diseases. Therefore, AD is considered the gateway to other allergic diseases. Currently, there is no cure, but the increasing numbers of innovative and targeted therapies hold promise for achieving disease control, including in patients with recalcitrant disease.^{5,6} To address these concerns, the 4th Global Allergy Forum (GAF) was held, with a focus on AD. The forum covered a wide range of topics, including education and issues related to neuroimmunology,

immunology, environmental factors, comorbidities, prevention, diagnosis, and treatment. The forum brought together experts from various specialties to discuss the latest research and advancements in the field and identify gaps or unmet medical needs. The key messages of the GAF were that atopic diseases are increasingly prevalent and are becoming a greater public health problem because broad environmental changes, including climate change, pollution, physio-chemical exposures, lifestyle, and psychosocial factors, are increasingly shown to act as drivers of these common diseases.^{7,8} Simultaneously, our knowledge of atopic diseases has expanded dramatically such that we now have new targeted therapies based on improved insight into the pathogenesis and concrete approaches for prevention and disease modification.⁹ This growing knowledge contrasts with the reduced focus on the successful implementation of these new and effective forms of therapy into clinical practice. In addition to extending our understanding of the pathophysiology of atopic diseases and developing therapeutic and preventative strategies, there was consensus that greater awareness, education, and translational research on implementation are needed. The forum also highlighted the importance of addressing the underlying causes of atopic diseases, such as passive environmental factors (e.g., air pollution, chemicals in food and

water, etc.) and active lifestyle choices to effectively manage or better prevent disease.

Overall, the GAF was an invaluable opportunity for experts and researchers to convene and discuss the latest developments and challenges in the field of atopic diseases. This platform allows for the sharing of knowledge and ideas and for identifying high-yield areas for further research and is crucial for advancing the diagnosis, treatment, and management of atopic diseases. The ultimate goal is to improve the health and resilience of people who face these challenges in a changing world.

After each GAF, a Davos Declaration is developed to disseminate knowledge and information on the topics discussed during the GAF. Previously, Declarations covered, including but not limited to, the need for interdisciplinary research on allergy and AD development,¹ prevention strategies for allergic diseases,² and the building of patient registries as the underpinning for precision medicine.³ For this Declaration the latest research on the environmental, immunological, and neurological influences on AD development was highlighted, and new strategies for education, prevention, and global- and individual-centered care were discussed. The main messages and identified gaps in AD and allergic diseases from the 2022 GAF are summarized below:

2 | EPITHELIAL BARRIER MAINTENANCE AND DISTURBANCES IN ATOPIC DISEASES

2.1 | Definition of the epithelial barrier

The epithelial barrier is one of the first interfaces between humans and their external environment and is a necessary adaptation for terrestrial life.^{10,11} Epithelial tissue has several functions, including (1) Barrier, (2) Secretion, (3) Excretion, (4) Absorption, (5) Filtration, (6) Diffusion, and (7) Sensing. For over two decades, the interactions between the epithelial barrier and the immune system have been investigated.¹² Skin barrier-related genes and their proteins, such as filaggrin, play a pivotal role in the formation of the cornified envelope in the stratum corneum. Mutations in the filaggrin gene and low copy numbers of filaggrin which lead to lower protein expression have been identified in patients with AD.¹³ In addition, filaggrin's organic acid breakdown products contribute to the acidic skin pH, which is important for the skin barrier, with rises in skin pH observed in filaggrin-mutant AD.¹⁴ An extensive epithelial barrier hypothesis has been proposed to explain the sharp increase in many chronic noncommunicable inflammatory diseases including AD in the last 60 years.¹⁵ It proposes that environmental exposure to certain substances (e.g., detergents, food emulsifiers) causes defective, or "leaky," epithelial barriers, contributing to allergies and other chronic diseases. As an early event, the impairment of the epithelial barrier results in the release of alarmins, followed by microbial alterations and potential translocation of the commensal bacteria and pathogenic or bacterial products to deeper tissues.^{11,15}

2.2 | The role of the skin barrier in the pathogenesis of AD

Recent environmental changes have now exposed the skin barrier to man-made exogenous stressors, with which the skin is functionally unsuited to cope. These exposures occurred primarily in the second half of the 20th century in industrialized regions but have expanded globally as a result of climate change and global industrialization. This daily exposure to a variety of toxins and chemicals can lead to a dysfunctional skin barrier, which is highly relevant to allergic diseases, especially AD. Many studies have demonstrated epidemiological evidence linking the development of AD to direct detergent exposure,¹⁵⁻¹⁷ and important changes in the epidermal lipid structure are observed in healthy infants before onset of AD.¹⁸ Barrier alteration may also occur following domestic exposure to "hard water", notably in individuals with filaggrin gene mutations¹⁹ pointing to an important gene-environment interaction.

2.3 | Skin immunity: Innate and adaptive responses and trained immunity

AD is dominated by a Th2 immune response in the skin, with additional yet varying contributions by the Th1, Th17, and Th22 immune pathways, as previously reviewed (Figure 1).²⁰⁻²² Activated Th2 cells release cytokines, mainly Interleukin (IL)-4 and IL-13, into the skin. These cytokines contribute to skin barrier dysfunction by suppressing the expression of barrier proteins, such as filaggrin.²³⁻²⁵ More recently, there is growing evidence that IL-13 may play a more prominent role than IL-4 in the pathogenesis of AD with suggestions that IL-13 is the key driver for AD pathology.²⁶ Both cytokines, IL-4 and IL-13, use the Type 2 IL-4 alpha receptor. Based on prior datasets showing increased IL-13 gene expression in AD skin, the expression of IL-13 was negatively correlated with skin barrier function genes, and blocking IL-13 with tralokinumab reversed IL-13-induced reduction of skin barrier-related genes expression in vitro (Figure 3).²⁵ Blocking IL-4 and IL-13 signaling has been shown to improve the clinical signs of AD, including skin barrier function.²⁷⁻³⁰ Early interventions to maintain the skin barrier may be essential to prevent epicutaneous antigen presentation and subsequent development of other allergic diseases, such as food allergy.^{31,32} However, when treatment is interrupted, the disease frequently relapses, suggesting the presence of memory cells in the skin and other pathogenic innate and adaptive immune mechanisms. Single-cell RNA-seq analyses of AD skin revealed detailed cell types and their activity^{33,34} and showed the persistence of Th2A cells, mature dendritic cells, and cytotoxic cells that persist even after 1 year of treatment.³³ In addition, the presence of innate lymphoid cells (ILC) and the inflammatory or innate memory of the epithelial stem cells in the skin raises the concept of a potential role for these cells in the persistence of the inflammatory lesions in AD.^{35,36} For example, inflammatory genes in these epithelial progenitor cells were activated more easily via secondary




FIGURE 1 Pathogenesis and mechanisms of atopic dermatitis (AD). Skin barrier disruption and Th2/Th22-deviated immune reactions are central abnormalities in AD. The barrier-disrupted epidermis releases abundant IL-33 and thymic stromal lymphopietin (TSLP), which activate dendritic cells and innate lymphoid cells (ILC), and then trigger the Th2 immune response. Th2/Th22 deviation is then further accelerated during disease progression. Th1 and Th17 inflammation can be found in the chronic phase of AD. In addition, Th2 cytokines (IL-4 and IL-13) stimulate B cells to produce IgE antibodies against allergens. IgE binds on the surface of mast cells (MC) and sensitizes them. Th2 cytokines such as IL-13 and IL-31 promotes itch, while IL-5 induces eosinophil production and activation.

and unrelated stimuli due to epigenetic and metabolic changes leading to the alterations in chromatin accessibility.³⁷

2.4 | Antimicrobial defenses in the skin

Constitutively produced and induced upon infection and skin injury, antimicrobial peptides (AMPs) represent the first line of defense to protect the skin from microbes. Differential expression of keratinocyte-derived AMPs, such as human beta-defensin 2 (HBD-2), HBD-3, LL-37, RNase7, and psoriasin, in AD skin as compared to healthy individuals and psoriasis patients are thought to contribute to the association of *Staphylococcus aureus* (*S. aureus*) and herpes simplex viral infections in AD.^{38–44} The stratum corneum is also a source of “Cationic Intrinsically Disordered Antimicrobial Peptides” (CIDAMPs).⁴⁵ Major CIDAMP sources are hornerin (HRNR), filaggrin-2 (FLG2), late cornified envelope proteins (LCEs),⁴⁶ and the spacer regions of filaggrin. Whereas

CIDAMPs express potent bactericidal activity at acidic pH, mainly towards gram-negative bacteria, palmitoylated CIDAMPs are highly potent *S. aureus*-cidal AMPs. CIDAMPs kill bacteria, like aminoglycosides, by targeting ribosomal proteins.⁴⁶ *S. aureus* secretes extracellular proteases, such as V8, or “SspA”, which cleave extracellular proteins to impair the skin barrier and potentially mediate itch.⁴⁷ Studies have demonstrated that HBD-2 prevents V8-mediated damage.⁴⁸

2.5 | Skin metabolism

Proper cell function depends on the efficient use of various metabolic pathways and on the availability of glucose, amino acids, lipids, minerals, and oxygen,⁴⁹ each of which are disrupted in AD and previously reviewed.⁵⁰ Inflammation in AD lesions is characterized by keratinocyte hyperproliferation and the expansion of inflammatory cells which suggests specific metabolic reprogramming of the skin.

AD patients show increased levels of circulating lactate which indicates a metabolic shift toward the anaerobic glycolysis pathway.⁵¹ As indicated by gene expression signatures, the glycolysis pathway is also differentially altered in AD lesions as compared to lesions in discoid lupus erythematosus.⁵² On the other hand, oxidative phosphorylation characterizes non-lesional skin in AD compared to healthy control. Lipid metabolism also plays an important role in the pathogenesis of AD.⁵³ Anti-IL-4/IL-13 treatment, that is, dupilumab, treatment can change the metabolome of AD lesions with clinical responders demonstrating pathway enrichment in glycerophospholipid metabolism and the TCA cycle.⁵⁴ These metabolism markers could be integral to resolving AD; for example, gut-derived short-chain fatty acids can improve the integrity of the epidermal barrier, early allergen sensitization, and disease development in AD mouse models.⁵⁵

2.6 | The sensory and adaptive roles of the skin barrier

The crosstalk between type 2 skin inflammation, neuroimmune dysfunction, and skin barrier dysfunction are prominent features of human AD pathobiology and eventually lead to chronic itch in AD.⁵⁶ During cutaneous neurogenic inflammation observed in both chronic pruritus and AD, somatosensory afferent nerve fibers are activated by itch-inducing mediators which are released by a variety of different cells in the skin, including damaged keratinocytes and immune cells such as T-cells, dendritic cells, basophils, mast cells, eosinophils, and ILC2. Many cytokines and pathways are involved in skin inflammation and itch, in particular type 2 cytokines including IL-4, IL-13, and IL-31, and the alarmins IL-33 and thymic stromal lymphopoietin (TSLP) (Figure 1). IL-4, IL-13, and IL-31 contribute to the persistence of itch by directly interacting with sensory neurons to sensitize them and induce itchiness.^{45,57} IL-33 is elevated in AD and chronic pruritus, with signaling from the IL-33 receptor on sensory neurons being necessary for inducing itch.^{46,58} Recently, Keren et al. reported that humanized mice^{48,59} showed characteristic neuro-immunological abnormalities such as β 2-adrenergic receptor downregulation with barrier dysfunction. The presence of chemical contaminants in epithelial tissue is associated with hypersensitivity, chronic inflammation, and oxidative stress, each of which leads to barrier defects in the epithelial tissues and affects the central nervous system.

3 | ENVIRONMENTAL CHANGES AS A DRIVING FORCE OF ATOPIC DISEASES

Understanding and combating atopic diseases requires a deeper consideration of the exposome, which is defined as one's exposures over a lifetime and how those exposures relate to one's health. The concerning rise in atopic diseases is strongly linked to environmental exposures on a background of genetic susceptibilities.⁶⁰ Increases in temperature, drought, wildfires, humidity, and pollution lead to

higher outdoor exposures to pollen, molds, parasites, smoke, and insects, as well as secondary changes in the composition of the indoor exposome.⁶¹ Air pollution—as a component of the exposome—contributes to changes in the global climate and vice versa and exacerbates allergic diseases, particularly asthma and AD.⁶² Thus, the components of the exposome as well as the timing of these exposures whether early in childhood or later in adulthood are critical to studying and reducing the prevalence of atopic diseases.⁶³ Infant immune development is strongly influenced by host biology and the environment. The “hygiene hypothesis” suggests that reduced microbial exposure in industrialized countries impairs immune development. Global studies correlate early-life microbiota with atopy, but the exact mechanisms are still being explored.^{48,64}

With warming climates, new allergens, for example, ticks and ragweed, are being introduced to previously less exposed regions. The Darwinian “survival of the fittest” theory portrays how invasive species outcompete the rich, diverse local fauna and flora, thereby massively changing the exposome.^{65,66} The loss of biodiversity in the macro- and microenvironment is associated with an increase in atopic diseases.⁶⁴ An illustrative example of the effects of environmental changes on allergic diseases is the increase in the tick population which corresponded with the first tick bite-transmitted allergic disease, the galactose- α 1,3-galactose (α -Gal) syndrome (AGS), commonly called “red meat allergy”.⁶⁷ Patients with AGS have IgE antibodies to the carbohydrate α -Gal, which is transmitted by tick bites, and suffer from urticaria to life-threatening anaphylaxis after ingesting the carbohydrate α -Gal which is found in mammalian (red) meat or mammalian products.⁶⁸⁻⁷⁰ The highly allergenic ragweed pollen (*Ambrosia artemisiifolia*) also reflects the effect of environmental changes as well as globalization on allergic diseases. Ragweed, an invasive flowering plant native to North America, has successfully expanded its presence across Europe and in particular within warmer climates, and is a source of concern for the increase of allergic diseases with warming temperatures.⁷¹⁻⁷⁵

3.1 | Protective environmental factors

In parallel with climate changes, naturally protective nutritional and environmental factors that counteract the development of allergies are also endangered in an increasingly urbanized world. People living in more rural areas are incorporating features of urban lifestyles. Industrialization in farming and food processing has been important for expanding food supplies, and the establishment of requirements for hygienic processes has reduced potential contamination and the risk of infections. However, the so-called “farm effect” that comprises various environmental and microbial exposures has been linked to lower rates of allergic diseases.⁷⁶ Food processing is linked to higher immunogenicity and allergenicity of proteins such as those found in milk.⁷⁷ Understanding how industrialization contributes to atopic diseases and how biodiversity is linked to atopic diseases is vital for developing possible preventive or therapeutic modalities⁷⁸ or nutritional interventions.⁷⁹

3.2 | Microbial aspects

The intricate relationship between the exposome and the host—particularly the cause-and-effect relationship between the microbiome and AD—remains complex and incompletely defined. One such connection between microbes and AD is skin pH: skin pH is elevated in AD⁸⁰ and the abundance of *S. aureus* in AD is correlated with a rise in skin pH.⁸¹ The challenge in elucidating causality is that human microbiome studies tend to examine associations in which skin microbiome changes are described alongside AD progression and treatment efficacy yet typically do not provide evidence of causality. Of note, studies have shown that *S. aureus* can elicit skin inflammation thus highlighting the complexity of the relationship between microbes and AD.⁸² In an infant cohort, reduced diversity of the skin microbiome at 2 months of age was predictive of subsequent development of AD in early childhood.⁸³ Further longitudinal human studies with standardized skin microbiome protocols should be conducted, addressing (a) a deeper understanding of the skin microbiome and (b) its potential use for personalized medicine in the future.

4 | CONCEPT OF IMMUNOLOGICAL MARCH ALONG THE COURSE OF AD

4.1 | Physiological development of the immune system versus immunological march in AD

The immune system is a dynamic construct that is constantly exposed and reacting to a variety of external and internal signals. During one's lifetime, even before birth, the immune system undergoes physiological development with an early-life education. This is followed by a robust, balanced immunity which includes an age-dependent appearance of various cell types, expression and function of pattern recognition receptors on antigen-presenting cells, and immunological responses classified as T helper cell and regulatory T responses based on specific cytokine profiles (Figure 2 and reviewed in⁸⁴). In contrast to this physiological development and age-related changes in immunity, immunological differences have been described during the course of AD, starting with the activation of the local innate immune system in the skin and followed by a Th2 dominant adaptive immune response. In fact, the increased epidermal levels of thymus and activation-regulated chemokine (TARC) in healthy infants predict the later onset of AD.⁸⁵ Of note, distinct Th1, Th17, and Th22 responses of varied intensities, centered around an initial core Th2 response, have been observed in studies performed in children, adolescents, and adults suffering from AD. The age-dependent increase of IFN- γ /Th1 in healthy children and adults (0–40 years) is absent or mostly obscured by the Th2 dominance in AD children.⁸⁶ While IL-13 and TARC are highly elevated in AD patients as compared to controls in all age groups, a steady increase of IL-6, IL-17A, and IL-22 with increasing age was observed in AD patients, whereas controls had constant or even decreased levels of these cytokines at ages less than 60-years-old.⁸⁷ Thus, these series

of immune deviations observed across different age groups in AD—termed the “immunological march”—clearly differ from physiological immune development.

A major gap in understanding the immunological march in AD exists because the majority of the data has been drawn from the cross-sectional studies of specific age groups that reflect certain characteristics of AD. To understand both the physiological immunodevelopment and the pathological deviations of the immunological march in AD patients, future longitudinal studies in patients are essential.

The term “atopic march” describes the development of AD followed by the clinical onset of other Th2-related atopic comorbidities such as allergic asthma, allergic rhinitis, food allergy, and eosinophilic esophagitis (EE) in distinct subgroups of patients.⁸⁸ However, necessary information on the detailed dynamics of the immunological march, its players, and a clear mechanistic link to the clinical trajectories of AD, including atopic march, is still missing. While epicutaneous sensitization leading to Th2-comorbidities has been reported, the other mechanisms are still enigmatic.⁸⁹ One of the gaps that need to be addressed is the unclear role of IgE in AD, whereas the role of IgE is well documented in other Th2 comorbidities. The role of the Th2-induced class switch of B cells to IgE production and the impact of IgE-specificity remains to be elucidated. Unsatisfactory results of IgE-targeted therapeutic approaches, such as omalizumab, in AD, show the need for a deeper understanding and the subsequent potential of precision medicine.⁹⁰ Furthermore, the immunological mechanisms associated with spontaneous remission or late-onset AD remain to be understood. Recent epidemiologic studies demonstrated that childhood-onset AD had higher odds of having asthma, food allergy, and multiple atopic co-morbidities, yet lower odds of allergic rhinitis, than adult-onset AD.^{91,92} Taken together, our understanding of the clinical link to the immunological march is still scarce. Several animal models of AD and other atopic diseases may allow insights into certain aspects of the underlying pathomechanisms.^{93,94} However, to understand the complexity of a constantly developing and dynamic atopic diathesis, novel animal models are urgently needed. Studies in dog breeds (e.g., Westie, Beagle, or Boxer) that are genetically prone to develop AD, live in similar conditions as humans, and, thus, share a comparable exposome and lifestyle may in many aspects provide additional information on the development of AD.⁹⁵ Therefore, communication and collaboration between veterinarians and human basic scientists should be expanded.

4.1.1 | Intervention strategies for the restoration of the physiological immuno-development

Under physiological conditions, the development of the immune system is actively influenced by diet and gut-microbial signals, both of which shape the immune response to its “normal” state, that is, default development. On the other hand, the immunological mechanisms occurring in the skin, such as an impaired epidermal barrier and activation of the innate immune system, may lead to chronic




FIGURE 2 Potential opportunities to modulate physiological immuno-development. Evolutionary aspects of physiological immune development in humans include early antigen exposure in utero, birth, and early life; each of which programs a balanced immune reactivity. This phase is usually followed by a fully balanced immune system over young and adult life that then becomes increasingly unbalanced and less efficient in old age due to immune senescence. Non-physiological processes, like urbanization, overpopulation, climate change, and environmental pollution, may interfere with this ideal concept by igniting a Th2-dominated march toward atopic dermatitis (AD). This immunological march can be facilitated by imbalanced signals from the gut and skin barrier. Genetic predisposition and exposome entry may both play a role and also render skin-barrier disruption as well as the Th2-associated inflammatory situation. Progressive AD may secondarily foster comorbidities at other organ sites than the skin, for instance, atherosclerosis and depression. Early intervention or immune education within the “programming”-phase may lead to complete remission and physiological immune development. At later time points, repetitive interventions—such as, changes in lifestyle, daily skin care, and dietary management—may be necessary to reach or almost reach a physiological immune condition. In persisting AD, a basic management strategy shall be continued, but with additional therapeutic interventions to control the chronic inflammation.

inflammation and thus changing a physiological path of the immunological march. This knowledge provides unique opportunities for distinct intervention strategies: (i) by providing natural immune

signals early in life (possibly during pregnancy) that booster its physiological development, (ii) by restoring the epidermal barrier function and reducing epicutaneous sensitization, (iii) by pharmacologic




FIGURE 3 Neuroendotypes of atopic dermatitis (AD). Itch is a universal symptom in AD, and several factors stratify the development and symptoms of itch across AD patients, suggesting that there are various neuroendotypes of itch in AD. By classifying a patient's neuroendotype, a precision medicine approach can be taken that can improve patient outcomes. The first step towards this requires more precise diagnostics and interdisciplinary work, alongside the development of new and neuroendotype-targeted therapies.

intervention, for example, treating skin inflammation early and intensively, or by a combination of those three. However, whether these measures are effective may depend on proper timing which still remains to be defined. For example, in adults, the positive effects from changing the environmental factors are usually not sustained, and a continuous behavior modification, for example, repeated exposure to microbiome-derived signals, may be necessary to retain the effect. Adapting the patients' life-style towards an atopic-protective one through diets, increased activity, and smoking cessation should be considered as therapeutic measure in the management of AD.^{96,97} Education of this should be included as part of patient care.

It is not known if there is a specific time-period in early life in which environmental or therapeutic interventions would have long-term benefits. A mother's diet during pregnancy can influence the child's risk of developing AD, suggesting that prenatal exposures are important.^{98,99} Also, exposure of the neonate to the maternal vaginal microbiome may reduce the risk for AD. Taken together, there is increasing evidence of opportunities to positively intervene early in life and educate the immune system in a way that has long-term effects which prevent the immunological march and its clinical correlate, the atopic march.

5 | NEUROIMMUNOLOGY, SYSTEMIC INFLAMMATION, AND COMORBIDITIES

In the realm of AD research, the study of neuroimmunology is increasingly recognized for its significance in elucidating the mechanisms by which systemic inflammation can influence neuro-immunological responses within the body, thereby underscoring the intricate bidirectional communication between the immune system and the nervous system in this dermatological disease.

5.1 | Pruritus—from neuroimmune to psychosomatic aspects

Itch, the unpleasant sensation leading to the desire to scratch, is the predominant symptom and a hallmark of AD.¹⁰⁰ Those suffering from AD identify itch and the visible presence of eczema, particularly on the face, as one of the most burdensome aspects of the disease with its presence frequently resulting in feelings of stigmatization among patients. The itch sensation is often present all day and disturbs sleep and regular life, including but not limited to, work capacity, school performance, social life, and relationships¹⁰¹ and these patients are afflicted with a vicious cycle of itching, scratching and inflammation. The mechanisms of itch are still not fully understood. Of the many factors influencing itch (Figure 3), the interplay among the nervous system (including the brain), the immune system, and the skin (e.g., mast cells) is likely key. Activation of sensory nerves transmits signals to the central nervous system (CNS); the CNS, in response, may modulate the skin's physiology by the release of hormones and the upregulation of neuropeptides and receptors in the nerves, a phenomenon described as the skin-brain axis.¹⁰² Since both itch and pain engage the same pathways, distinct cytokines appear to drive these clinically different sensations.¹⁰³ Of note, sensory nerves involved in itch also induce a response by releasing neuropeptides such as calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), and substance P, which is termed neurogenic inflammation.^{104,105} The complex pathophysiology of itch is orchestrated not just by nerves but also by a close bidirectional interaction of nerves with immune cells, such as T-cells, eosinophils, basophils, and mast cells, contributing to neuroinflammation.¹⁰⁶ Various mediators released by immune cells can directly act on nerves. These include histamine,^{107,108} tryptase, leukotrienes,^{109,110} neuropeptides,^{111,112} cytokines (e.g., IL-4, IL-5, IL-13,

IL-31),^{26,113-116} and alarmins (e.g., TSLP¹¹⁷). The blockade of IL-4 receptor alpha and IL-31 receptor alpha as well as inhibition of JAK1/2 lead to the control of itch and have an important role in the sensation of itch. Furthermore, endogenous opioids and their receptors located on central and peripheral nerves and various skin cells may contribute to pruritus and changes in the skin barrier.¹¹⁸

The role of the nervous system and the psyche of itch should not be underestimated. Imaging studies of the brain have clearly shown activation of a variety of CNS areas including some of the limbic system during itch sensations.¹¹⁹ In somatoform pruritus, psychosocial factors contribute to the induction of itch. Verbal suggestions or instructions have a potent impact on the perception of itch.^{120,121} On the other hand, pruritus can induce or enhance the development of psychosomatic reactions such as anxiety or depression.¹²² Several studies have shown an association between AD and psychiatric comorbidities.^{123,124}

A concept that is heavily debated is the degree to which pruritic diseases such as AD can be seen as diseases with systemic inflammation^{34,125} acting not only on the nervous system, but also on other organs such as the heart, lung, or gut. In AD, for instance, certain patient groups have an increased risk of cardiovascular diseases.¹²⁶⁻¹²⁸ It can be assumed that sleep disturbances and reduced physical activity may enhance the risk of cardiovascular diseases in AD. Interestingly, the previously reported dose-response relationship between the severity of AD and the risk of cardiovascular diseases¹²⁶ points towards a more prominent systemic inflammation in severe AD, albeit the absolute risk is minimal.

Inflammatory mediators of pruritus can be found in skin diseases as well as in gastrointestinal¹²⁹ and lung diseases¹³⁰ and may underline the importance of studying comorbidities in pruritic diseases. Of note, sneezing and coughing in response to nasal and airway irritation, respectively, have been described as similar corresponding responses by these other organs as the scratching response to itch in the skin. Those reactions may originate as host-protective behavioral responses.¹³¹

Regarding environmental factors, different trigger factors of itch such as allergens and microbes have been identified. Sensory neurons can detect molecular ligands of bacteria, especially seen for *S. aureus*, and influence the sensation of itch and pain.^{47,132} Beside the skin microbiome, the gut microbiome may contribute to pruritus (via a gut-skin and/or gut-brain axis). However, specific mechanisms have not yet been identified.

6 | THERAPEUTIC, EDUCATIONAL, AND GLOBAL ECONOMIC ASPECTS

6.1 | New treatments have revolutionized AD management

In the last few years, targeted treatments for AD have advanced dramatically. The biological agents dupilumab (anti-IL-4Rα), tralokinumab (anti-IL-13), and lebrikizumab (anti-IL-13) along with the Janus kinase inhibitors (JAKi) baricitinib, upadacitinib and




FIGURE 4 The aspects that should be considered in a precision medicine approach for the treatment of atopic dermatitis (AD). Because AD is a highly heterogeneous disease, a precision medicine approach is a more suitable treatment strategy. In selecting targeted therapy, one should consider comorbidities, risk of adverse events, age, and other factors. A biomarker method for the stratification of different endotypes and phenotypes is urgently needed. One approach to facilitate the identification of different therapy responders is to perform a combined data analysis of current AD registries and clinical trials. Certain comorbidities have approved indications in addition to AD for distinct targeted systemic therapies (green) including dupilumab for asthma, prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSWNP), eosinophilic esophagitis (EE); baricitinib for alopecia areata (AA) and rheumatoid arthritis (RA); upadacitinib for RA, psoriatic arthritis (PsA), ankylosing spondylitis (AS), axial spondyloarthritis (SpA), and non-radiographic ulcerative colitis (nr-SpA).^{134,136} In addition, AD patients can be susceptible to other diseases with an increased risk of adverse events to distinct therapies (red). This includes, but is not limited to susceptibility to conjunctivitis, herpes simplex virus (HSV), eczema herpeticum (EH), zoster, venous thromboembolism (VT), or comorbidities including cardiovascular diseases.

abrocitinib have been approved with indication for systemic therapy in moderate-to-severe AD in Europe.^{5,133–137} Because of these potential additional applications of these therapies, consideration of comorbidities is crucial for selecting the proper treatment alongside other aspects such as short- and long-term efficacy, safety profile, etc.^{5,88,133,134,138,139} (Figure 4). Ongoing clinical trials have shown further possible applications for these agents as well as even more possible treatments.^{5,133,134}

Despite these advances and the high prevalence of AD, significant global, economic, and educational inequalities in the treatment of AD still remain.¹⁴⁰ To ensure that every AD patient receives optimal treatment, patients, healthcare providers, and the pharmaceutical industry must work together to advance science and therapeutic management.

6.2 | Global consensus on individual treatment goals

One of the biggest challenges in the treatment of AD is the lack of global consensus on defining individual treatment goals and assessing the severity of the disease, including sensory and psychosocial symptoms.^{141,142} AD is a clinically heterogeneous disease with a large range of clinical phenotypes and underlying endotypes.^{92,96,143–147} These AD subtypes are suggested by the variability in treatment responses including the onset, speed, and duration of response; side effect profiles (e.g., ocular involvement)^{134,136}; and biomarker responses^{24,148–151} such as improved responses of subgroups with higher baseline levels of certain biomarkers (e.g., periostin).^{147–149,152–158} Moreover, AD in different ethnic backgrounds and climates (e.g. tropics) is characterized by different underlying pathomechanisms, for example, Th2-dominated inflammation in patients of European descent or the additional Th17 component in AD patients of Asian and African descent, which requires adapted therapeutic approaches.^{145,158,159} Future directions for this research include studying how AD varies pathologically across various ethnicities, as well as the role played by the patients' environments. This would encourage the development of more efficient and cost-effective diagnostics.^{5,148}

Importantly, a global consensus is needed on the definition of appropriate targets for AD treatment, disease severity assessments, and who should receive systemic therapy. Many have attempted to define such including the European Task Force on Atopic Dermatitis (ETFAD) and International Eczema Council (IEC).^{141,160} Increased levels of severity-associated biomarkers, which suggest a systemic impact of skin inflammation, have been observed in a significant number of patients with low to moderate AD.¹⁴⁷

The new European Guidelines already address a more personalized implementation of systemic therapy beyond the hierarchical cut-offs of objective severity scores.^{134,136,155} These guidelines suggest the implementation of both clinician- and patient-reported outcome measures in accordance with the Harmonizing Outcome Measures for Eczema Initiative.^{134,136,155} In addition, they recommend systemic therapy in case of functional or social indications,

as defined as an insufficient response to “appropriately conducted topical therapy” or the inability to participate in daily life due to insufficiently controlled disease despite being “under an adequate treatment regimen”.¹³⁴

6.3 | Management and efficient treatment of AD as a preventive tool for AD progression and atopic march—toward disease modification

The new availability of highly effective treatment options may create a potential window of opportunity for disease prevention or alteration of progression in the early stages of AD.¹⁶¹ Early sufficient treatment with topical therapy and additional targeted systemic treatment potentially could suppress disease severity and reduce the number of flares, while inducing long-term remission of AD symptoms and reducing the risk of developing type-2 comorbidities.¹⁶¹

With the widespread use of systemic treatment and improved disease control, several questions regarding the practical aspects of disease management have emerged such as the definition of “remission” and “disease modification” in the context of AD, the required duration of systemic treatment in well-controlled AD, the stability of response under dosage tapering or prolonged dosage intervals, the potential combining of systemic therapies, and the definition of patients with insufficient response to available therapies (summarized in Figure 5). Additionally, it can be expected that multiple challenges will emerge. These issues include the treatment of patients with complicated medical profiles, for example, patients who are pregnant or have metastatic malignancies, and practical issues involving mounting healthcare costs due to high drug prices not covered through insurance.


Well-designed prospective trials that test various combinations of therapies to attain therapeutic remission and the compilation of both clinical and laboratory data from patient registries and academic studies are needed to help address these questions. In addition, concerns about cost-effectiveness must be balanced with the consequences of a reduced quality of life, restricted work capability, and negatively impacted life expectancy.

6.4 | Global aspects of AD management

It should be noted that current, modern systemic therapies like JAKi^{5,162} are not available or are limited in many regions worldwide. In many regions, simple treatments such as emollients or topical steroids are considered luxury products and are thus out of reach. Lack of competent or trained medical practitioners and poor medical infrastructure are additional hurdles. This situation may change now that the WHO has begun to integrate common skin diseases into its global health strategy.¹⁶³

The Guidelines should provide clear, practical, and realistic recommendations that optimize all available therapies and support

FIGURE 5 Issues to be further addressed regarding systemic therapies in atopic dermatitis (AD).



shared decision-making. In addition, the opportunities for further research into the prevention of AD and the modification of the disease are of eminent importance. Aspects regarding climate change and planetary health¹⁶⁴ should also be included.

6.5 | Education programs are powerful tools in the toolkit for managing AD

A global plan for patient education incorporating online information and digital tools might improve the care of AD patients even in underserved areas.¹⁶⁵ A lack of education on topical therapies has resulted in widespread weaknesses in the management of AD. Many patients are unaware of the full range of treatment options available, and healthcare providers may not have the knowledge or resources to provide optimal care. These issues highlight the need for greater awareness, education, and resources for AD patients and healthcare providers and the need for collaboration of all involved to develop effective educational activities and programs.¹⁶⁶ Education gaps, among both patients and healthcare professionals regarding optimal AD management should be addressed through targeted education interventions.^{167,168} The education in AD management should consider the family as an integral factor in holistic care and the AD patient's age. Effective education optimally includes the delivery of information and an experience in which all parties (giver and recipient) are invested, motivated, and engaged, and then behavioral changes can be observed at the end. With the launch of the Global Atlas on Atopic Dermatitis (GAAD) program, an attempt to broaden education has been made and ideally may result in more widespread awareness and knowledge of AD globally.¹⁶⁵

Evidence-based, holistic, and cutting-edge educational methods should be prioritized. The needs assessments via “GAP analyses” are also an essential prerequisite. Findings from modern teaching studies and resultant interactive methods, such as “blended learning”, and “flipped classroom”, and innovative approaches such as “design thinking”, should be incorporated to

impart the knowledge and skills to teach as efficiently as possible.¹⁶⁹ By selecting adequate education methods, motivation for change and better allergy competence can be achieved, leading also to altered behavior and improved performance and patient outcomes (see Figure 6).

Evidence-based educational principles, interprofessional learning, social aspects of learning, cultural differences, digital educational tools, and cost-effectiveness should be incorporated, leading to a true commitment to change.¹⁷⁰ For improved AD self-management with reduced distress, higher quality of life, and improved long-term cost-effectiveness of AD care, patients can benefit enormously from well-trained healthcare professionals and a patient learning program that is standardized to provide comprehensive education and flexible to meet individual needs, based on mindful and empathic approaches.

The community should establish an interprofessional group, consisting of physicians, nurses, dieticians, psychologists, and patients, to identify areas for educational research in AD, using the most successful practices determined from other chronic disease areas, for example, diabetes and wound care. Furthermore, accommodating different learning styles and preferences would enhance the effectiveness of these educational experiences. There should also be a move to Massive Open Online Courses (MOOCs).^{171,172}

6.6 | Digital medicine in allergic diseases: harnessing wearables, AI, and exposome monitoring for enhanced therapeutic management and prevention

Advances in digital medicine provide a unique opportunity to contribute to both the systematic investigations of the exposome and the therapeutic management of allergic diseases, including education, personalized reminders, and monitoring of patient-reported outcomes.¹⁷³ We propose that technological advances can play a role in improving the management of AD. Tools such as “wearables” and artificial




FIGURE 6 Design for effective continuing professional development: A path to facilitate the translation of acquired competencies into clinical daily practice. The focus is on teaching and learning methods that illuminate motives for change so that physicians and healthcare providers can develop and further their allergy competencies. The ultimate goal is to bring about positive behavior and performance changes among healthcare professionals, leading to better patient management and outcomes.

intelligence methods might be used to help measure and interpret changes in one's environment.¹⁷⁴ This could be used for individualized prevention, for example, by alerting an individual with asthma or AD in a region with elevated levels of air pollution which could lead to disease exacerbations.⁶¹ The potential value in monitoring the exposome through the use of apps to provide rich data for research, prediction of disease development, therapeutic management, education, and prevention purposes must also be balanced with the privacy risk. The international panel highlighted the importance of securely protecting personal data given the large potential range of applications in the field of digital medicine concerning the management of comprehensive therapy in chronic inflammatory allergic diseases.

7 | FUTURE DIRECTIONS: ADDRESSING IDENTIFIED GAPS AND NEEDS

7.1 | Epithelial barrier and environmental factors

Investigating how environmental factors such as climate change, genetic predispositions, and changes in the skin microbiome influence the weakening of the epithelial barrier in AD, and assessing the need for multidimensional analysis of these factors, is crucial for developing preventative strategies, personalized therapies, and understanding geographical variations in AD incidence.

- *Impact of climate change:* What is the specific impact of climate change-related factors (e.g., increasing temperatures, humidity changes, exposure to new allergens, and altered pollen patterns) on the exacerbation or development of AD?
- *Genetic versus environmental factors:* To what extent do genetic predispositions versus environmental factors contribute to the weakening of the epithelial barrier in AD?
- *Skin Microbiome Dynamics:* How do changes in the skin microbiome, influenced by environmental factors, contribute to the disruption of the epithelial barrier in AD?
- *Longitudinal studies on environmental changes:* What are the long-term, combined effects of ongoing environmental changes (like urbanization, lifestyle changes, and dietary shifts) on the prevalence and severity of AD?
- *Need for:* Multidimensional analysis of the exposome and the reactome in time and space including longitudinal studies and registries on an international level is needed.
- *Interaction between skin barrier and immune system:* How do changes in the skin barrier, influenced by environmental factors, interact with the immune system, and how does this interaction contribute to systemic inflammation and the development of further comorbidities?
- *Preventive strategies:* Can modifications in environmental exposure (like reducing exposure to pollutants or allergens) prevent impairment of the epithelial barrier and prevent or mitigate AD?

- *Geographical variations in AD incidence:* Are there geographical trends in AD incidence that correlate with specific environmental or climate factors?
- *Therapeutic approaches targeting the barrier:* What are the most effective therapeutic approaches to strengthen the epithelial barrier in AD, considering environmental and microbiome influences?
- *Personalized microbiome-based therapies:* How can individual variations in the skin microbiome be leveraged to develop personalized treatment strategies for AD?

7.2 | Atopic march, immunological march, and neuroimmunology

There is a need for a comprehensive understanding of the multifaceted factors influencing the progression of AD to other atopic diseases, encompassing immunological, molecular, psycho-immunological, and environmental aspects, including the roles of skin barrier dysfunction and microbiome-immune interactions

- *Progression from AD to other atopic diseases:* What are the key immunological and molecular mechanisms driving the progression from AD to other atopic diseases, such as asthma or allergic rhinitis?
- *Early-life factors in atopic march:* How do early-life exposures and genetic predispositions contribute to the initiation of the atopic march starting with AD?
- *Role of skin barrier dysfunction:* How does skin barrier dysfunction in AD influence systemic immune responses and facilitate the progression of the atopic march?
- *Psycho-immunological factors in AD progression:* What role do psycho-immunological factors play in the progression from AD to subsequent stages of the atopic march?
- *Characterize immunosenescence in AD:* What is the role of immunosenescence especially in adult- and late-onset AD versus healthy individuals?
- *Biomarkers predictive of atopic march progression:* Are there identifiable biomarkers in early AD that can predict the likelihood of progression along the atopic march?
- *Impact of early intervention in AD:* How does early intervention in AD alter the course of the atopic march, particularly in terms of immunological and psycho-immunological outcomes?
- *Interaction between the microbiome and immune system in atopic march:* How does the interaction between the skin and gut microbiome and the immune system influence the progression of the atopic march?
- *Psychological stress and AD progression:* How does psychological stress in individuals with AD contribute to the immunological changes associated with the atopic march?
- *Influence of environmental factors on atopic march:* How do environmental factors, such as pollutants and allergens, impact the transition from AD to other atopic diseases?
- *Preventive strategies targeting the atopic march:* What preventive strategies can be employed in the early stages of AD to halt or slow down the progression of the atopic march?
- *Leverage knowledge for prevention:* How can interventions, for example, selective substitution of microbes, diet, and pharmacological approaches, impact the immunological march and how can the switch to a physiological immuno-development be systematically evaluated?
- *Development of more effective management strategies for AD, particularly in addressing the mechanisms of itch and reducing the associated patient stigmatization:* Understanding of the intricate interaction between the nervous system (including the brain), the immune system, and the skin.
- *Neuronal signaling:* How can an enhanced understanding of neuroimmune circuits and neuronal signaling contribute to optimizing strategies for controlling the pathological mechanisms in AD, including inflammation, barrier dysfunction, and pruritus?

7.3 | Education and prevention

Effective management of AD requires multimodal education and advocacy campaigns, timely interventions considering individual differences, and collaborative efforts among key organizations to enhance treatment compliance, raise disease awareness, and develop precise, stage-specific therapy

- *Primary to tertiary prevention:* What impact would a multimodal education and awareness campaign, targeting patients, their families, politicians, policymakers, medical doctors, nurses, and other care providers, have on improving the understanding of current therapeutic options for a specific condition, and how might such educational programs for patients enhance compliance with their therapies, thereby leading to better clinical outcomes?
- *Effect of outreach campaigns:* How can advocacy efforts for AD patients, in collaboration with patient organizations, effectively raise awareness about the severe impact of itch, sleep loss, and other mental health aspects on the quality of life (QoL) in the context of AD, and what strategies would be most effective in addressing these challenges?
- *Interventions over the lifespan:* Considering the evidence that early interventions can prevent allergies, how do the timing and nature of these interventions, especially during early life and pregnancy, compare to adult interventions in effectively preventing or altering the course of AD?
- *Optimized therapeutic approaches:* How can the therapeutic approaches be optimized according to disease stage along with the immunological march of AD, and is there a potential for a precision medicine approach according to stages of the immunological march?
- *Ethnic and sex-related differences:* Are there individual differences, such as ethnic and sex-related differences, that need

to be considered when developing treatment and prevention strategies?

- *Collaboration of societies:* It is recommended that organizations such as the International Society for Atopic Dermatitis, International Eczema Council, and HOME initiative collaborate in research, education, and advocacy efforts for patients with AD.
- *Education for both the caregivers and the patient level* should be implemented, because it is a highly effective tool to improve the awareness and management of AD.

7.4 | Identified gaps in diagnosis and therapy

These research goals are crucial for improving the quality of health-care globally, ensuring equitable treatment for patients worldwide, and recognizing the diverse ways in which diseases can manifest and affect individuals differently.

- *Identifying variations:* Research on how different countries and cultures define and treat the same disease, particularly focusing on how they consider sensory and psychosocial symptoms in their treatment goals.
- *Analyzing the impact of diverse definitions:* Evaluating the impact of these varying definitions and treatment approaches on patient outcomes. This includes understanding how different perceptions of disease severity can influence treatment effectiveness and patient satisfaction.
- *Developing global standards:* Working towards creating a more standardized, globally accepted set of guidelines for defining and treating the disease. This would involve incorporating a broad range of perspectives and ensuring that these guidelines are adaptable to different cultural contexts.
- *Enhancing patient-centered care:* Ensuring that these global standards are flexible enough to be tailored to individual patient needs, particularly in addressing sensory and psychosocial aspects, which may be more subjective and vary greatly among individuals.
- *Cross-cultural collaboration and education:* Promoting cross-cultural collaboration among healthcare professionals to share knowledge and best practices, and educating them about the importance of considering cultural differences in treatment approaches.

AUTHOR CONTRIBUTIONS

T.H.C., P.S.G., T.B., H.H.K., E.J.J., J.A., N.H., and M.Y. wrote the text in part. Figures were provided by M.Y., N.H., L.M., P.S.G., M.U., and D.S.P. All authors reviewed the manuscript and gave consent to the manuscript.

AFFILIATIONS

¹Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany

²Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany

³Christine Kühne-Center for Allergy Research and Education (CK-CARE),

Medicine Campus, Davos, Switzerland

⁴Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland

⁵AbbVie Inc., North Chicago, Illinois, USA

⁶Center for Allergy and Environment (ZAUM), Technische Universität München, Germany

⁷Davos Biosciences, Davos, Switzerland

⁸University of Minnesota, Minneapolis, Minnesota, USA

⁹Department of Immunology and Microbiology, The LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark

¹⁰Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland

¹¹Faculty of Medicine, University of Zürich, Zürich, Switzerland

¹²Almirall Hermal GmbH, Reinbek, Germany

¹³Hochgebirgsklinik Davos, Davos, Switzerland

¹⁴LEO Pharmaceutical Products Sarath Ltd, Zürich, Switzerland

¹⁵Pfizer Switzerland AG, Zürich, Switzerland

¹⁶Department of Pediatrics, Division of Respiratory Medicine and Allergology, Bern University Hospital, Bern, Switzerland

¹⁷Department of BioMedical Research (DBMR), University of Bern, Bern, Switzerland

¹⁸Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark

¹⁹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

²⁰Psychosomatic Department, Hochgebirgsklinik, Davos, Switzerland

²¹Pfizer, Istanbul, Turkey

²²Universitair Ziekenhuis, Brussel, Belgium

²³Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany

²⁴Diakonessenhuis Utrecht Zeist Doorn Locatie Utrecht, Erasmus MC, University Medical Center Utrecht, Utrecht, Netherlands

²⁵Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland

²⁶Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria

²⁷The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria

²⁸Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

²⁹Environmental Health, LLC, Durham, North Carolina, USA

³⁰Ostschweizer Kinderspital St. Gallen, St.Gallen, Switzerland

³¹Department of Dermatology, University of California Davis, Sacramento, California, USA

³²Stanford University School of Medicine, Stanford, California, USA

³³APC Microbiome Ireland, University College Cork, Cork, Ireland

³⁴Department of Medicine and School of Microbiology, University College Cork, Cork, Ireland

³⁵Faculty of Medicine, Antananarivo, Madagascar

³⁶Institute of Laboratory Medicine, Philipps University, Marburg, Germany

³⁷Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Munich, Germany

³⁸Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland

³⁹Klinik für Dermatologie, Venerologie und Allergologie,

Universitätsklinikum Schleswig-Holstein (UK-SH), Kiel, Germany

⁴⁰Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁴¹Institute of Pharmacology, University of Bern, Bern, Switzerland

⁴²Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany

⁴³Center for Chronic Pruritus and Department of Dermatology, University Hospital Münster, Münster, Germany

⁴⁴Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar

⁴⁵Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar

- ⁴⁶Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar
- ⁴⁷School of Medicine, Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar
- ⁴⁸College of Medicine, Qatar University, Doha, Qatar
- ⁴⁹College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
- ⁵⁰Department of Dermatology, Weill Cornell Medicine, New York, New York, USA
- ⁵¹INSERM 1312, University of Bordeaux, Bordeaux, France
- ⁵²Department of Dermatology, Faculdade de Medicina, Hospital das Clínicas, Universidade de São Paulo, São Paulo, São Paulo, Brazil
- ⁵³Bencard Allergie GmbH München, Munich, Germany
- ⁵⁴Department of Dermatology and Venerology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
- ⁵⁵Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
- ⁵⁶Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany
- ⁵⁷Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institute and Karolinska University Hospital Stockholm, Solna, Sweden
- ⁵⁸Department of Pneumology, Intensive Care Medicine, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany
- ⁵⁹Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany
- ⁶⁰Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany
- ⁶¹Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lubeck, Germany
- ⁶²Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
- ⁶³Department of Medicine Solna, Division of Dermatology and Venereology, Karolinska Institutet, Stockholm, Sweden

ACKNOWLEDGMENTS

We thank Andreas Gerads for creative and graphical support in the figure design. Open Access funding enabled and organized by Projekt DEAL.

FUNDING INFORMATION

There is no funding for this article.

CONFLICT OF INTEREST STATEMENT

The authors declare that this publication was conducted in the absence of any commercial or financial relationships that could be understood as a potential conflict of interest. Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

DATA AVAILABILITY STATEMENT

Research data are not shared.

ORCID


Claudia Traidl-Hoffmann  <https://orcid.org/0000-0001-5085-5179>

Cezmi A. Akdis  <https://orcid.org/0000-0001-8020-019X>

Mübecel Akdis  <https://orcid.org/0000-0003-0554-9943>

Katja Bärenfaller  <https://orcid.org/0000-0002-1904-9440>

Charlotte Menné Bonfeld  <https://orcid.org/0000-0002-0523-6229>

Marie Charlotte Brügggen  <https://orcid.org/0000-0002-8607-6254>

Danielle Fehr  <https://orcid.org/0000-0001-6361-3662>

Lena H. Garvey  <https://orcid.org/0000-0002-7777-4501>

Nadine Herrmann  <https://orcid.org/0000-0003-4924-2281>

Dirk Jan Hijnen  <https://orcid.org/0000-0003-3379-3425>

Alan D. Irvine  <https://orcid.org/0000-0002-9048-2044>

Erika Jensen-Jarolim  <https://orcid.org/0000-0003-4019-5765>

Laura Maintz  <https://orcid.org/0000-0001-6053-1530>

Svenja Müller  <https://orcid.org/0000-0002-2118-959X>

Kari Nadeau  <https://orcid.org/0000-0002-2146-2955>

Liam O'Mahony  <https://orcid.org/0000-0003-4705-3583>


Harald Renz  <https://orcid.org/0000-0003-0602-7215>

Caroline Roduit  <https://orcid.org/0000-0002-5988-0570>

Mari Sasaki  <https://orcid.org/0000-0003-1590-3838>

Dagmar Simon  <https://orcid.org/0000-0001-8965-9407>

Milena Sokolowska  <https://orcid.org/0000-0001-9710-6685>

Jacob Pontoppidan Thyssen  <https://orcid.org/0000-0003-3770-1743>

Stephan Traidl  <https://orcid.org/0000-0003-4806-599X>

Marianne van Hage  <https://orcid.org/0000-0003-3091-1596>

Christian Virchow  <https://orcid.org/0000-0003-4291-1956>

Mitamura Yasutaka  <https://orcid.org/0000-0001-6389-9285>

Alexander Zink  <https://orcid.org/0000-0001-9313-6588>

Peter Schmid-Grendelmeier  <https://orcid.org/0000-0003-3215-3370>

REFERENCES

1. Ring J, Akdis C, Behrendt H, et al. Davos declaration: allergy as a global problem. *Allergy*. 2012;67(2):141-143. doi:10.1111/j.1398-9995.2011.02770.x
2. Ring J, Akdis C, Lauener R, Schäppi G, et al. Global allergy forum and second Davos declaration 2013 allergy: barriers to cure—challenges and actions to be taken. *Allergy*. 2014;69(8):978-982. doi:10.1111/all.12406
3. Bieber T, Akdis C, Lauener R, Traidl-Hoffmann C, et al. Global allergy forum and 3rd Davos declaration 2015: atopic dermatitis/eczema: challenges and opportunities toward precision medicine. *Allergy*. 2016;71(5):588-592. doi:10.1111/all.12857
4. Elezbawy B, Fasseeh AN, Fouly E, Tannira M, et al. Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa region. *Dermatol Ther*. 2023;13(1):131-146. doi:10.1007/s13555-022-00857-0
5. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. *Nat Rev Drug Discov*. 2022;21(1):21-40. doi:10.1038/s41573-021-00266-6
6. Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. *J Allergy Clin Immunol*. 2023;151(3):756-766. doi:10.1016/j.jaci.2022.08.026
7. Lunjani N, Ambikan AT, Hlela C, et al. Rural and urban exposures shape early life immune development in south African children with atopic dermatitis and nonallergic children. *Allergy*. 2023;79:65-79. doi:10.1111/all.15832

8. Pawankar R, Akdis CA. Climate change and the epithelial barrier theory in allergic diseases: a one health approach to a green environment. *Allergy*. 2023;78(11):2829-2834. doi:10.1111/all.15885
9. Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. *Nat Rev Drug Discov*. 2023;22(8):662-680. doi:10.1038/s41573-023-00735-0
10. Mitamura Y, Ogulur I, Pat Y, et al. Dysregulation of the epithelial barrier by environmental and other exogenous factors. *Contact Derm*. 2021;85(6):615-626. doi:10.1111/cod.13959
11. Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Epithelial barrier hypothesis: effect of the external exposome on the microbiome and epithelial barriers in allergic disease. *Allergy*. 2022;77(5):1418-1449. doi:10.1111/all.15240
12. Trautmann A, Akdis M, Kleemann D, et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. *J Clin Invest*. 2000;106(1):25-35. doi:10.1172/JCI9199
13. Stefanovic N, Irvine AD. Filaggrin and beyond: new insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. *Ann Allergy Asthma Immunol*. 2023;132:187-195. doi:10.1016/j.anai.2023.09.009
14. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol*. 2013;131(2):280-291. doi:10.1016/j.jaci.2012.12.668
15. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? *Nat Rev Immunol*. 2021;21(11):739-751. doi:10.1038/s41577-021-00538-7
16. Xian M, Wawrzyniak P, Rückert B, et al. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. *J Allergy Clin Immunol*. 2016;138(3):890-893.e9. doi:10.1016/j.jaci.2016.07.003
17. Tanzer J, Meng D, Ohsaki A, et al. Laundry detergent promotes allergic skin inflammation and esophageal eosinophilia in mice. *PLoS One*. 2022;17(6):e0268651. doi:10.1371/journal.pone.0268651
18. Rinnov MR, Halling AS, Gerner T, et al. Skin biomarkers predict development of atopic dermatitis in infancy. *Allergy*. 2023;78(3):791-802. doi:10.1111/all.15518
19. Halling AS, Bager P, Skov L, et al. The interaction between filaggrin mutations and hard domestic water and the risk of early-onset atopic dermatitis. *Br J Dermatol*. 2020;183(2):406-407. doi:10.1111/bjd.18965
20. Renert-Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. *J Allergy Clin Immunol*. 2021;148(1):148-163. doi:10.1016/j.jaci.2021.01.001
21. Pavel AB, Renert-Yuval Y, Wu J, et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in non-lesional skin. *Allergy*. 2021;76(1):314-325. doi:10.1111/all.14490
22. Kortekaas Krohn I, Aerts JL, Breckpot K, et al. T-cell subsets in the skin and their role in inflammatory skin disorders. *Allergy*. 2022;77(3):827-842. doi:10.1111/all.15104
23. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol*. 2009;124(3 Suppl 2):R7-R12. doi:10.1016/j.jaci.2009.07.012
24. Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. *Allergy*. 2020;75(1):54-62. doi:10.1111/all.13954
25. Tollenaere MAX, Litman T, Moebus L, et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin-13 and modulated by tralokinumab in vitro. *Acta Derm Venereol*. 2021;101(4):adv00447. doi:10.2340/00015555-3810
26. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. *N Engl J Med*. 2020;382(8):706-716. doi:10.1056/NEJMoa1908316
27. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med*. 2014;371(2):130-139. doi:10.1056/NEJMoa1314768
28. Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. *Allergy*. 2022;77(11):3388-3397. doi:10.1111/all.15432
29. Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. *J Am Acad Dermatol*. 2023;88(4):816-823. doi:10.1016/j.jaad.2022.11.047
30. Rohner MH, Thormann K, Cazzaniga S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. *Allergy*. 2021;76(4):1268-1270. doi:10.1111/all.14664
31. Brough HA, Lanser BJ, Sindher SB, et al. Early intervention and prevention of allergic diseases. *Allergy*. 2022;77(2):416-441. doi:10.1111/all.15006
32. Sindher SB, Long A, Chin AR, et al. Food allergy, mechanisms, diagnosis and treatment: innovation through a multi-targeted approach. *Allergy*. 2022;77(10):2937-2948. doi:10.1111/all.15418
33. Bangert C, Rindler K, Krausgruber T, et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R α blockade. *Sci Immunol*. 2021;6(55):eabe2749. doi:10.1126/sciimmunol.abe2749
34. Zhang B, Roesner LM, Traidl S, et al. Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. *Allergy*. 2023;78(2):439-453. doi:10.1111/all.15486
35. Naik S, Larsen SB, Gomez NC, et al. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. *Nature*. 2017;550(7677):475-480. doi:10.1038/nature24271
36. Alkon N, Bauer W, Krausgruber T, et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. *J Allergy Clin Immunol*. 2022;149(2):624-639. doi:10.1016/j.jaci.2021.07.025
37. Naik S, Fuchs E. Inflammatory memory and tissue adaptation in sickness and in health. *Nature*. 2022;607(7918):249-255. doi:10.1038/s41586-022-04919-3
38. Gläser R, Harder J, Lange H, Bartels J, Christophers E, Schröder JM. Antimicrobial psoriasis (S100A7) protects human skin from *Escherichia coli* infection. *Nat Immunol*. 2005;6(1):57-64. doi:10.1038/ni1142
39. Murdoch CC, Skaar EP. Nutritional immunity: the battle for nutrient metals at the host-pathogen interface. *Nat Rev Microbiol*. 2022;20(11):657-670. doi:10.1038/s41579-022-00745-6
40. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med*. 2002;347(15):1151-1160. doi:10.1056/NEJMoa021481
41. Harder J, Dressel S, Wittersheim M, et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. *J Invest Dermatol*. 2010;130(5):1355-1364. doi:10.1038/jid.2009.432
42. Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. *Allergy*. 2021;76(10):3017-3027. doi:10.1111/all.14853
43. Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human β -defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. *Br J Dermatol*. 2010;163(3):659-661. doi:10.1111/j.1365-2133.2010.09892.x
44. Latendorf T, Gerstel U, Wu Z, et al. Cationic intrinsically disordered antimicrobial peptides (CIDAMPs) represent a new paradigm of innate defense with a potential for novel anti-infectives. *Sci Rep*. 2019;9(1):3331. doi:10.1038/s41598-019-39219-w

45. Niehues H, Tsoi LC, van der Krieken DA, et al. Psoriasis-associated late cornified envelope (LCE) proteins have antibacterial activity. *J Invest Dermatol*. 2017;137(11):2380-2388. doi:10.1016/j.jid.2017.06.003
46. Gerstel U, Latendorf T, Bartels J, Becker A, Tholey A, Schröder JM. Hornerin contains a linked series of ribosome-targeting peptide antibiotics. *Sci Rep*. 2018;8(1):16158. doi:10.1038/s41598-018-34467-8
47. Deng L, Costa F, Blake KJ, et al. *S. aureus* drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. *Cell*. 2023;186(24):5375-5393.e25. doi:10.1016/j.cell.2023.10.019
48. Shelley JR, McHugh BJ, Wills J, et al. A mechanistic evaluation of human beta defensin 2 mediated protection of human skin barrier in vitro. *Sci Rep*. 2023;13(1):2271. doi:10.1038/s41598-023-29558-0
49. Man K, Kutayavin VI, Chawla A. Tissue immunometabolism: development, physiology, and pathobiology. *Cell Metab*. 2017;25(1):11-26. doi:10.1016/j.cmet.2016.08.016
50. Afghani J, Traidl-Hoffmann C, Schmitt-Kopplin P, Reiger M, Mueller C. An overview of the latest metabolomics studies on atopic eczema with new directions for study. *Int J Mol Sci*. 2022;23(15):8791. doi:10.3390/ijms23158791
51. Ottas A, Fishman D, Okas TL, et al. Blood serum metabolome of atopic dermatitis: altered energy cycle and the markers of systemic inflammation. *PLoS One*. 2017;12(11):e0188580. doi:10.1371/journal.pone.0188580
52. Martínez BA, Shrotri S, Kingsmore KM, Bachali P, Grammer AC, Lipsky PE. Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. *Sci Adv*. 2022;8(17):eabn4776. doi:10.1126/sciadv.abn4776
53. Yin H, Qiu Z, Zhu R, et al. Dysregulated lipidome of sebum in patients with atopic dermatitis. *Allergy*. 2023;78(6):1524-1537. doi:10.1111/all.15569
54. Zhang L, Wen X, Hou Y, et al. Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab. *Front Immunol*. 2022;13:1002536. doi:10.3389/fimmu.2022.1002536
55. Trompette A, Pernot J, Perdijk O, et al. Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation. *Mucosal Immunol*. 2022;15(5):908-926. doi:10.1038/s41385-022-00524-9
56. Steinhoff M, Ahmad F, Pandey A, et al. Neuroimmune communication regulating pruritus in atopic dermatitis. *J Allergy Clin Immunol*. 2022;149(6):1875-1898. doi:10.1016/j.jaci.2022.03.010
57. Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. *Cell*. 2017;171(1):217-228.e13. doi:10.1016/j.cell.2017.08.006
58. Trier AM, Mack MR, Fredman A, et al. IL-33 signaling in sensory neurons promotes dry skin itch. *J Allergy Clin Immunol*. 2022;149(4):1473-1480.e6. doi:10.1016/j.jaci.2021.09.014
59. Keren A, Reich K, Bertolini M, et al. Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants. *Allergy*. 2023;78(6):1538-1553. doi:10.1111/all.15635
60. Stefanovic N, Irvine AD, Flohr C. The role of the environment and exposure in atopic dermatitis. *Curr Treat Options Allergy*. 2021;8(3):222-241. doi:10.1007/s40521-021-00289-9
61. Wang SP, Stefanovic N, Orfali RL, et al. Impact of climate change on atopic dermatitis: a review by the international eczema council. *Allergy*. 2024;79:1455-1469. doi:10.1111/all.16007
62. Pfaar O, Klimek L, Jutel M, Akdis CA, et al. COVID-19 pandemic: practical considerations on the organization of an allergy clinic—an EAACI/ARIA position paper. *Allergy*. 2021;76(3):648-676. doi:10.1111/all.14453
63. Fadadu RP, Green M, Jewell NP, Grimes B, Vargo J, Wei ML. Association of exposure to wildfire air pollution with exacerbations of atopic dermatitis and itch among older adults. *JAMA Netw Open*. 2022;5(10):e2238594. doi:10.1001/jamanetworkopen.2022.38594
64. Donald K, Finlay BB. Early-life interactions between the microbiota and immune system: impact on immune system development and atopic disease. *Nat Rev Immunol*. 2023;23(11):735-748. doi:10.1038/s41577-023-00874-w
65. Agache I, Sampath V, Aguilera J, et al. Climate change and global health: a call to more research and more action. *Allergy*. 2022;77(5):1389-1407. doi:10.1111/all.15229
66. Perera F, Nadeau K. Climate change, fossil-fuel pollution, and children's health. *N Engl J Med*. 2022;386(24):2303-2314. doi:10.1056/NEJMra2117706
67. Kiewiet MBG, Grundström J, Apostolovic D, et al. Elucidating the α -gal syndrome at the molecular allergen level. *Allergy*. 2021;76(5):1576-1578. doi:10.1111/all.14660
68. Apostolovic D, Mihailovic J, Commins SP, et al. Allergenomics of the tick *Ixodes ricinus* reveals important α -gal-carrying IgE-binding proteins in red meat allergy. *Allergy*. 2020;75(1):217-220. doi:10.1111/all.13978
69. Apostolovic D, Tran TAT, Hamsten C, Starkhammar M, Cirkovic Velickovic T, van Hage M. Immunoproteomics of processed beef proteins reveal novel galactose- α -1,3-galactose-containing allergens. *Allergy*. 2014;69(10):1308-1315. doi:10.1111/all.12462
70. Perusko M, Apostolovic D, Kiewiet MBG, et al. Bovine γ -globulin, lactoferrin, and lactoperoxidase are relevant bovine milk allergens in patients with α -gal syndrome. *Allergy*. 2021;76(12):3766-3775. doi:10.1111/all.14889
71. Effner R, Hiller J, Eyerich S, et al. Cytochrome P450s in human immune cells regulate IL-22 and c-kit via an AHR feedback loop. *Sci Rep*. 2017;7:44005. doi:10.1038/srep44005
72. Zhao F, Elkelish A, Durner J, et al. Common ragweed (*Ambrosia artemisiifolia* L.): allergenicity and molecular characterization of pollen after plant exposure to elevated NO₂. *Plant Cell Environ*. 2016;39(1):147-164. doi:10.1111/pce.12601
73. Oeder S, Alessandrini F, Wirz OF, et al. Pollen-derived nonallergenic substances enhance Th2-induced IgE production in B cells. *Allergy*. 2015;70(11):1450-1460. doi:10.1111/all.12707
74. El Kelish A, Zhao F, Heller W, et al. Ragweed (*Ambrosia artemisiifolia*) pollen allergenicity: SuperSAGE transcriptomic analysis upon elevated CO₂ and drought stress. *BMC Plant Biol*. 2014;14:176. doi:10.1186/1471-2229-14-176
75. Beck I, Jochner S, Gilles S, et al. High environmental ozone levels lead to enhanced allergenicity of birch pollen. *PLoS One*. 2013;8(11):e80147. doi:10.1371/journal.pone.0080147
76. Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms and childhood asthma. *N Engl J Med*. 2011;364(8):701-709. doi:10.1056/NEJMoa1007302
77. Jensen SA, Fiocchi A, Baars T, et al. Diagnosis and rationale for action against cow's milk allergy (DRACMA) guidelines update—III—cow's milk allergens and mechanisms triggering immune activation. *World Allergy Organ J*. 2022;15(9):100668. doi:10.1016/j.waojou.2022.100668
78. Deckers J, Lambrecht BN, Hammad H. How a farming environment protects from atopy. *Curr Opin Immunol*. 2019;60:163-169. doi:10.1016/j.coi.2019.08.001
79. Bartosik T, Jensen SA, Afify SM, et al. Ameliorating atopy by compensating micronutritional deficiencies in immune cells: a double-blind placebo-controlled pilot study. *J Allergy Clin Immunol Pract*. 2022;10(7):1889-1902.e9. doi:10.1016/j.jaip.2022.02.028
80. Bigliardi PL. Role of skin pH in psoriasis. *Curr Probl Dermatol*. 2018;54:108-114. doi:10.1159/000489524
81. Hülpmusch C, Tremmel K, Hammel G, et al. Skin pH-dependent *Staphylococcus aureus* abundance as predictor for increasing atopic dermatitis severity. *Allergy*. 2020;75(11):2888-2898. doi:10.1111/all.14461

82. Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2019;143(1):26-35. doi:10.1016/j.jaci.2018.11.015
83. Halling AS, Fritz BG, Gerner T, et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high-risk children. *J Invest Dermatol.* 2023;143(10):2030-2038. e6. doi:10.1016/j.jid.2023.03.1682
84. Georgountzou A, Papadopoulos NG. Postnatal innate immune development: from birth to adulthood. *Front Immunol.* 2017;8:957. doi:10.3389/fimmu.2017.00957
85. Halling AS, Rinnov MR, Ruge IF, et al. Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis. *J Allergy Clin Immunol.* 2023;151(6):1550-1557.e6. doi:10.1016/j.jaci.2022.11.023
86. Kawamoto N, Kaneko H, Takemura M, et al. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children. *Pediatr Allergy Immunol.* 2006;17(2):125-133. doi:10.1111/j.1399-3038.2005.00363.x
87. Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China. *J Eur Acad Dermatol Venereol.* 2020;34(10):2346-2352. doi:10.1111/jdv.16346
88. Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JL. Comorbidities of atopic dermatitis-what does the evidence say? *J Allergy Clin Immunol.* 2023;151(5):1155-1162. doi:10.1016/j.jaci.2022.12.002
89. Tham EH, Rajakulendran M, Lee BW, Van Bever HPS. Epicutaneous sensitization to food allergens in atopic dermatitis: what do we know? *Pediatr Allergy Immunol.* 2020;31(1):7-18. doi:10.1111/pai.13127
90. Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. *World Allergy Organ J.* 2021;14(3):100519. doi:10.1016/j.waojou.2021.100519
91. Abuabara K, Ye M, McCulloch CE, et al. Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife. *J Allergy Clin Immunol.* 2019;144(3):710-719. doi:10.1016/j.jaci.2019.05.040
92. Maintz L, Schmitz MT, Herrmann N, et al. Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood. *Allergy.* 2023;78(8):2181-2201. doi:10.1111/all.15721
93. Kim D, Kobayashi T, Nagao K. Research techniques made simple: mouse models of atopic dermatitis. *J Invest Dermatol.* 2019;139(5):984-990.e1. doi:10.1016/j.jid.2019.02.014
94. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. *J Invest Dermatol.* 2009;129(1):31-40. doi:10.1038/jid.2008.106
95. Marsella R. Atopic dermatitis in domestic animals: what our current understanding is and how this applies to clinical practice. *Vet Sci.* 2021;8(7):124. doi:10.3390/vetsci8070124
96. Maintz L, Welchowski T, Herrmann N, et al. Machine learning-based deep phenotyping of atopic dermatitis: severity-associated factors in adolescent and adult patients. *JAMA Dermatol.* 2021;157(12):1414-1424. doi:10.1001/jamadermatol.2021.3668
97. Tan KJ, Nakamizo S, Lee-Okada HC, et al. A Western diet alters skin ceramides and compromises the skin barrier in ears. *J Invest Dermatol.* 2022;142(7):2020-2023.e2. doi:10.1016/j.jid.2021.12.017
98. Venter C, Palumbo MP, Sauder KA, et al. Associations between child filaggrin mutations and maternal diet with the development of allergic diseases in children. *Pediatr Allergy Immunol.* 2022;33(3):e13753. doi:10.1111/pai.13753
99. Venter C, Greenhawt M, Meyer RW, et al. EAACI position paper on diet diversity in pregnancy, infancy and childhood: novel concepts and implications for studies in allergy and asthma. *Allergy.* 2020;75(3):497-523. doi:10.1111/all.14051
100. Jafferany M, Davari ME. Itch and psyche: psychiatric aspects of pruritus. *Int J Dermatol.* 2019;58(1):3-23. doi:10.1111/ijd.14081
101. Grundmann S, Ständer S. Chronic pruritus: clinics and treatment. *Ann Dermatol.* 2011;23(1):1-11. doi:10.5021/ad.2011.23.1.1
102. Darsow U, Drzezga A, Frisch M, et al. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. *J Invest Dermatol.* 2000;115(6):1029-1033. doi:10.1046/j.1523-1747.2000.00193.x
103. Trier AM, Mack MR, Kim BS. The neuroimmune axis in skin sensation, inflammation, and immunity. *J Immunol.* 2019;202(10):2829-2835. doi:10.4049/jimmunol.1801473
104. Ekblom A, Lundeberg T, Wahlgren CF. Influence of calcitonin gene-related peptide on histamine- and substance P-induced itch, flare and weal in humans. *Skin Pharmacol.* 1993;6(3):215-222. doi:10.1159/000211138
105. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. *J Pain.* 2013;14(11):1289-1303. doi:10.1016/j.jpain.2013.03.010
106. Steinhoff M, Buddenkotte J, Lerner EA. Role of mast cells and basophils in pruritus. *Immunol Rev.* 2018;282(1):248-264. doi:10.1111/imr.12635
107. Graham HT, Lowry OH, Wahl N, Priebe MK. Mast cells as sources of tissue histamine. *J Exp Med.* 1955;102(3):307-318. doi:10.1084/jem.102.3.307
108. Malaviya R, Morrison AR, Pentland AP. Histamine in human epidermal cells is induced by ultraviolet light injury. *J Invest Dermatol.* 1996;106(4):785-789. doi:10.1111/1523-1747.ep12346356
109. Wang F, Yang TLB, Kim BS. The return of the mast cell: new roles in neuroimmune itch biology. *J Invest Dermatol.* 2020;140(5):945-951. doi:10.1016/j.jid.2019.12.011
110. Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch. *Cell.* 2021;184(2):422-440.e17. doi:10.1016/j.cell.2020.12.033
111. Kaur G, Singh N, Jaggi AS. Mast cells in neuropathic pain: an increasing spectrum of their involvement in pathophysiology. *Rev Neurosci.* 2017;28(7):759-766. doi:10.1515/revneuro-2017-0007
112. Kushnir-Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. *J Allergy Clin Immunol.* 2007;119(2):498-499. doi:10.1016/j.jaci.2006.09.003
113. Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. *J Allergy Clin Immunol.* 1998;102(3):491-502. doi:10.1016/s0091-6749(98)70140-x
114. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. *J Exp Med.* 1992;176(5):1381-1386. doi:10.1084/jem.176.5.1381
115. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. *J Exp Med.* 1995;181(4):1373-1380. doi:10.1084/jem.181.4.1373
116. Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. *Allergy.* 2018;73(1):29-36. doi:10.1111/all.13239
117. Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. *Cell.* 2013;155(2):285-295. doi:10.1016/j.cell.2013.08.057
118. Ständer S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. *Regul Pept.* 2002;110(1):75-83. doi:10.1016/s0167-0115(02)00159-3
119. Pfab F, Kirchner MT, Huss-Marp J, et al. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient- and examiner-blinded,

randomized, placebo-controlled, crossover trial. *Allergy*. 2012;67(4):566-573. doi:10.1111/j.1398-9995.2012.02789.x

120. Stumpf A, Zerey V, Heuft G, Ständer S, Pflleiderer B, Schneider G. Itch perception and skin reactions as modulated by verbal suggestions: role of participant's and investigator's sex. *Acta Derm Venereol*. 2016;96(5):619-623. doi:10.2340/00015555-2336

121. Bartels DJP, van Laarhoven AIM, Stroo M, et al. Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. *PLoS One*. 2017;12(9):e0182959. doi:10.1371/journal.pone.0182959

122. Stumpf A, Schneider G, Ständer S. Psychosomatic and psychiatric disorders and psychologic factors in pruritus. *Clin Dermatol*. 2018;36(6):704-708. doi:10.1016/j.clindermatol.2018.08.015

123. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. *J Invest Dermatol*. 2015;135(4):984-991. doi:10.1038/jid.2014.530

124. Dieris-Hirche J, Gieler U, Kupfer JP, Milch WE. Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis. *Hautarzt*. 2009;60(8):641-646. doi:10.1007/s00105-009-1744-y

125. Roesner LM, Farag AK, Pospich R, Traidl S, Werfel T. T-cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin-focused, allergen-driven disease. *Allergy*. 2022;77(9):2737-2747. doi:10.1111/all.15272

126. Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. *J Allergy Clin Immunol*. 2019;143(5):1821-1829. doi:10.1016/j.jaci.2018.11.030

127. Thyssen JP, Halling-Overgaard AS, Andersen YMF, Gislason G, Skov L, Egeberg A. The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol*. 2018;178(6):1272-1279. doi:10.1111/bjd.16215

128. Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. *BMJ*. 2018;361:k1786. doi:10.1136/bmj.k1786

129. Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. *Autoimmun Rev*. 2017;16(1):55-63. doi:10.1016/j.autrev.2016.09.014

130. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. *Front Med*. 2021;8:639097. doi:10.3389/fmed.2021.639097

131. Anzelc M, Burkhart CG. Pain and pruritus: a study of their similarities and differences. *Int J Dermatol*. 2020;59(2):159-164. doi:10.1111/ijd.14678

132. Chiu IM, Heesters BA, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation. *Nature*. 2013;501(7465):52-57. doi:10.1038/nature12479

133. Mohr N, Augustin M, Zeervi L, et al. Determinants of costs and benefits in atopic dermatitis routine care in Germany. *J Eur Acad Dermatol Venereol*. 2022;36(9):1450-1455. doi:10.1111/jdv.18169

134. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I-systemic therapy. *J Eur Acad Dermatol Venereol*. 2022;36(9):1409-1431. doi:10.1111/jdv.18345

135. Bieber T, Paller AS, Kabashima K, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. *J Eur Acad Dermatol Venereol*. 2022;36(9):1432-1449. doi:10.1111/jdv.18225

136. Wollenberg A, Kinberger M, Arents B, et al. First update of the living European guideline (EuroGuiDerm) on atopic eczema. *J Eur Acad Dermatol Venereol*. 2023;37(11):e1283-e1287. doi:10.1111/jdv.19269

137. Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. *N Engl J Med*. 2023;388(12):1080-1091. doi:10.1056/NEJMoa2206714

138. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. *JAMA Dermatol*. 2022;158(5):523-532. doi:10.1001/jamadermatol.2022.0455

139. Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults. *J Am Acad Dermatol*. 2022;86(6):1335-1336.e18. doi:10.1016/j.jaad.2022.01.009

140. Akdis CA, Akdis M, Boyd SD, Sampath V, Galli SJ, Nadeau KC. Allergy: mechanistic insights into new methods of prevention and therapy. *Sci Transl Med*. 2023;15(679):eadd2563. doi:10.1126/scitranslmed.add2563

141. De Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. *Acta Derm Venereol*. 2021;101(2):adv00402. doi:10.2340/00015555-3751

142. Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. *J Allergy Clin Immunol*. 2022;149(6):1899-1911. doi:10.1016/j.jaci.2022.03.017

143. Ständer S. Atopic dermatitis. *N Engl J Med*. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911

144. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4(1):1. doi:10.1038/s41572-018-0001-z

145. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. *J Allergy Clin Immunol*. 2019;143(1):1-11. doi:10.1016/j.jaci.2018.10.032

146. Brunner PM, He H, Pavel AB, et al. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. *J Am Acad Dermatol*. 2019;81(2):510-519. doi:10.1016/j.jaad.2019.04.036

147. Maintz L, Welchowski T, Herrmann N, et al. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis. *Allergy*. 2023;78:1554-1569. doi:10.1111/all.15647

148. Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-a review on behalf of the international eczema council. *J Allergy Clin Immunol*. 2021;147(4):1174-1190.e1. doi:10.1016/j.jaci.2021.01.013

149. Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. *J Allergy Clin Immunol*. 2019;143(1):135-141. doi:10.1016/j.jaci.2018.05.029

150. Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. *J Invest Dermatol*. 2017;137(3):603-613. doi:10.1016/j.jid.2016.09.037

151. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. *J Allergy Clin Immunol*. 2014;133(6):1626-1634. doi:10.1016/j.jaci.2014.03.003

152. Bakker DS, Ariens LFM, Giovannone B, et al. EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. *Allergy*. 2020;75(12):3287-3289. doi:10.1111/all.14492

153. Olydam JI, de Wijs LEM, Dik WA, Røpke MA, Da Rosa JC, Hijnen DJ. EASI p-EASI: predicting disease severity in patients with atopic dermatitis treated with tralokinumab. *J Invest Dermatol*. 2022;142(12):3335-3337.e1. doi:10.1016/j.jid.2022.06.008

154. Thijs JL, Drylewicz J, Bruijnzeel-Koomen CAFM, et al. EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with cyclosporin A. *Allergy*. 2019;74(3):613-617. doi:10.1111/all.13651

155. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema—part II: non-systemic treatments and treatment recommendations for special AE patient populations. *J Eur Acad Dermatol Venereol*. 2022;36(11):1904-1926. doi:[10.1111/jdv.18429](https://doi.org/10.1111/jdv.18429)
156. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. *Br J Dermatol*. 2019;181(3):459-473. doi:[10.1111/bjd.17869](https://doi.org/10.1111/bjd.17869)
157. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. *J Am Acad Dermatol*. 2021;84(1):139-147. doi:[10.1016/j.jaad.2020.08.051](https://doi.org/10.1016/j.jaad.2020.08.051)
158. Lang CCV, Renert-Yuval Y, Del Duca E, et al. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. *Ann Allergy Asthma Immunol*. 2021;127(3):334-341. doi:[10.1016/j.anai.2021.04.023](https://doi.org/10.1016/j.anai.2021.04.023)
159. Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. *Ann Allergy Asthma Immunol*. 2019;122(5):449-455. doi:[10.1016/j.anai.2018.11.015](https://doi.org/10.1016/j.anai.2018.11.015)
160. Thyssen JP, Vestergaard C, Deleuran M, et al. European task force on atopic dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2020;34(12):e839-e842. doi:[10.1111/jdv.16716](https://doi.org/10.1111/jdv.16716)
161. Bieber T. In search of the holy grail in atopic dermatitis: will dupilumab become the first disease-modifying atopic dermatitis drug? *J Allergy Clin Immunol*. 2023;151(3):694-696. doi:[10.1016/j.jaci.2022.12.824](https://doi.org/10.1016/j.jaci.2022.12.824)
162. Thyssen JP, Schmid-Grendelmeier P. Long-term disease control in atopic dermatitis using biologics. *Lancet*. 2023;401(10372):172-173. doi:[10.1016/S0140-6736\(22\)02347-9](https://doi.org/10.1016/S0140-6736(22)02347-9)
163. Schmid-Grendelmeier P, Rapelanoro Rabenja F, Beshah AM, et al. How to integrate atopic dermatitis in the management of skin neglected tropical diseases in sub-Saharan Africa? *J Eur Acad Dermatol Venereol*. 2023;37:e1040-e1042. doi:[10.1111/jdv.19096](https://doi.org/10.1111/jdv.19096)
164. Herrmann A, Lenzer B, Müller BS, et al. Integrating planetary health into clinical guidelines to sustainably transform health care. *Lancet Planet Health*. 2022;6(3):e184-e185. doi:[10.1016/S2542-5196\(22\)00041-9](https://doi.org/10.1016/S2542-5196(22)00041-9)
165. The International Eczema Council, The International Society for Atopic Dermatitis, The European Taskforce for Atopic Dermatitis, The International League of Dermatological Societies, The International Alliance of Dermatology Patient Organizations (Global Skin). The Global Atopic Dermatitis Atlas. Accessed December 18, 2023. <https://www.eczemacouncil.org/global-atopic-dermatitis-atlas>
166. Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. *J Allergy Clin Immunol*. 2017;140(3):845-853.e3. doi:[10.1016/j.jaci.2017.01.029](https://doi.org/10.1016/j.jaci.2017.01.029)
167. Traidl S, Lang C, Schmid-Grendelmeier P, Werfel T, Heratizadeh A. Comprehensive approach: current status on patient education in atopic dermatitis and other allergic diseases. *Handb Exp Pharmacol*. 2022;268:487-500. doi:[10.1007/164_2021_488](https://doi.org/10.1007/164_2021_488)
168. Gerth van Wijk R, Mülleneisen N, Demoly P, et al. The roadmap for allergology in Europe: the European training requirements for the specialty of allergology. *Allergy*. 2021;76(5):1588-1591. doi:[10.1111/all.14614](https://doi.org/10.1111/all.14614)
169. Goi HC, Tan WL. Design thinking as a means of citizen science for social innovation. *Front Sociol*. 2021;6:629808. doi:[10.3389/fsoc.2021.629808](https://doi.org/10.3389/fsoc.2021.629808)
170. Straub Piccirillo D, Schmid-Grendelmeier P, Hitzler M, Lauener R. Continuing medical education activities for improved management of allergy patients. *Allergy*. 2018;73(6):1351-1353. doi:[10.1111/all.13443](https://doi.org/10.1111/all.13443)
171. Guest C, Wainwright P, Herbert M, Smith IM. Driving quality improvement with a massive open online course (MOOC). *BMJ Open Qual*. 2021;10(1):e000781. doi:[10.1136/bmjopen-2019-000781](https://doi.org/10.1136/bmjopen-2019-000781)
172. Nieder J, Nayna Schwerdtle P, Sauerborn R, Barteit S. Massive open online courses for health worker education in low- and middle-income countries: a scoping review. *Front Public Health*. 2022;10:891987. doi:[10.3389/fpubh.2022.891987](https://doi.org/10.3389/fpubh.2022.891987)
173. Gudmundsdóttir SL, Ballarini T, Ámundadóttir ML, et al. Engagement, retention, and acceptability in a digital health program for atopic dermatitis: prospective interventional study. *JMIR Form Res*. 2023;7:e41227. doi:[10.2196/41227](https://doi.org/10.2196/41227)
174. Kiani C, Steiner C, Zink A. Smart skin—a new technology in the area of digital dermatology. *Dermatologie (Heidelb)*. 2022;73(11):891-900. doi:[10.1007/s00105-022-05066-6](https://doi.org/10.1007/s00105-022-05066-6)

How to cite this article: Traidl-Hoffmann C, Afghani J, Akdis C, et al. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration. *Allergy*. 2024;79:2605-2624. doi:[10.1111/all.16247](https://doi.org/10.1111/all.16247)